BioTech Futures - Research

PDRN Research and Product Development

At BioTech Futures we study regenerative compounds that improve skin structure and resilience. A core focus is PDRN (polydeoxyribonucleotide), a DNA fragment known to support fibroblast activity, collagen synthesis, and post‑procedure recovery. Our team explores both fish‑derived and vegan analog formats, with delivery systems that aim for high effect and low irritation.

Clinical heritage

Medical use informed the cosmetic rise of PDRN

PDRN first built its reputation in clinical settings for tissue support and post‑procedure care. Professional lines such as Rejuran helped popularize the category and drew attention to the regenerative potential of DNA fragments when paired with procedures.

Vogue highlights Rejuran’s PDRN ampoule as a best‑overall option in its PDRN roundup, noting its anti‑aging and barrier support profile.

Consumer traction

Everyday formats: toners and serums

Mainstream brands now use PDRN in daily products such as toners and peptide serums for hydration, calming, and texture improvement. These formats introduced PDRN to sensitive‑skin users.

Glamour’s editors report visible soothing and glow benefits from PDRN serums after regular use.

Vegan direction

Plant‑derived options and kits

Some brands now offer plant‑sourced PDRN analogs and home kits that pair PDRN essences with supportive steps. This aligns with our research into animal‑free nucleotide sources.

Vogue and other outlets have profiled VT’s high‑ppm PDRN essence among notable options for hydration and firmness.

Mechanism

How it works

PDRN provides DNA fragments that can signal repair pathways and support fibroblasts. In cosmetics, this is pursued for elasticity, fine‑line reduction, and recovery support. BioTech Futures investigates micro‑carrier delivery to improve consistency and comfort.

Targets skin structure through fibroblast support
Aims to improve elasticity and barrier quality
Pairs well with hydrating agents and gentle peptides

Our direction

PDRN CellRenew™ concept

We are evaluating a vegan PDRN analog combined with peptides and a light, fast‑absorbing base. The target is visible firmness by week four, texture and fine‑line improvements by week six, and strong tolerance for daily use.

For investors and partners, we can share bench data and protocol outlines upon request.

Interested in collaborations or pilot studies?